Enzymotec Ltd. (NASDAQ:ENZY) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Zacks Investment Research cut shares of Enzymotec from a “hold” rating to a “sell” rating in a research note on Monday, May 22nd. One investment analyst has rated the stock with a sell rating and three have given a hold rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $8.00.

Enzymotec (NASDAQ:ENZY) remained flat at $9.90 during midday trading on Friday. The company had a trading volume of 12,125 shares. Enzymotec has a 12-month low of $5.20 and a 12-month high of $10.55. The firm’s 50 day moving average price is $8.23 and its 200 day moving average price is $8.46. The company’s market capitalization is $226.70 million.

Enzymotec (NASDAQ:ENZY) last announced its quarterly earnings data on Wednesday, May 17th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by $0.03. The firm had revenue of $12 million during the quarter, compared to the consensus estimate of $14.23 million. Enzymotec had a negative net margin of 9.50% and a negative return on equity of 2.06%. The business’s revenue was down 14.3% compared to the same quarter last year. During the same period last year, the business earned $0.09 earnings per share. Equities analysts expect that Enzymotec will post $0.21 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Enzymotec Ltd. (NASDAQ:ENZY) Upgraded to Hold by ValuEngine” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/12/enzymotec-ltd-nasdaqenzy-upgraded-to-hold-by-valuengine.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its stake in Enzymotec by 12.3% in the fourth quarter. Renaissance Technologies LLC now owns 290,000 shares of the biotechnology company’s stock worth $1,900,000 after buying an additional 31,700 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Enzymotec by 3.2% in the first quarter. Acadian Asset Management LLC now owns 237,184 shares of the biotechnology company’s stock worth $2,088,000 after buying an additional 7,322 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D boosted its stake in Enzymotec by 12.5% in the first quarter. State of New Jersey Common Pension Fund D now owns 28,110 shares of the biotechnology company’s stock worth $247,000 after buying an additional 3,113 shares during the last quarter. 27.93% of the stock is currently owned by institutional investors and hedge funds.

About Enzymotec

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.